Psoriasis, hair repigmentation studies top dermatology reads for week

Positive 5-year efficacy and safety results for Cosentyx from a phase 3 long-term extension study in patients with moderate-to-severe plaque psoriasis was among the top read articles of the past week on Healio.com/Dermatology.

Other widely-read articles included findings that patients with lung cancer who received immunotherapy experienced hair repigmentation, with the majority also experiencing good clinical response:

Novartis confirms 5-year efficacy for Cosentyx for psoriasis

Novartis has reported positive 5-year efficacy and safety results for Cosentyx from a phase 3 long-term extension study in patients with moderate-to-severe plaque psoriasis.

Data from the study will be presented at a medical congress in the second half of 2017, according to a news release. Read more

Research suggests link between hidradenitis suppurativa, dysbiotic cutaneous microbiome

Researchers found that the microbiome in hidradenitis suppurativa lesional and nonlesional skin differed significantly from the skin of healthy controls, suggesting a link between dysbiotic cutaneous microbiome and the skin disease, according to published study results in JAMA Dermatology.

Researchers in Denmark studied punch biopsy specimens from 30 patients with hidradenitis suppurativa (HS; mean age, 46.9 years; 63% female) and 24 healthy controls (mean age, 32.2 years; 54% female) from Oct. 1, 2014, to Aug. 1, 2016. Read more

Immunotherapy for lung cancer leads to hair repigmentation

Patients with lung cancer who were received immunotherapy experienced hair repigmentation, with the majority also experiencing good clinical response, according to recently study results in JAMA Dermatology.

Researchers in Barcelona, Spain, conducted a case series of 14 patients (mean age, 64.9 years; 13 men) with lung cancer who experienced hair repigmentation after anti-programmed cell death 1 (anti-PD-1) and anti-programmed cell death ligand 1 (anti-PD-L1) therapy. Read more

Kyntheum receives EU approval for treating adults with psoriasis

AstraZeneca and MedImmune announced that LEO Pharma has been granted marketing authorization in all 28 EU member countries plus Iceland, Liechtenstein and Norway for Kyntheum for treating moderate-to-severe plaque psoriasis in adults who are candidates for systemic therapy.

Kyntheum (brodalumab) is the only biologic that selectively targets the interleukin 17 (IL-17) receptor subunit to block the biological activity of several pro-inflammatory IL-17 cytokines involved in plaque formation, according to a news release. Read more

FDA lifts clinical hold on trial for alopecia areata

Concert Pharmaceuticals has announced that the FDA has lifted the clinical hold on the company’s CTP-543 phase 2a clinical trial for adults with alopecia areata.

The clinical stage biopharmaceutical company will amend the protocol for the study to evaluate two doses of CTP-543 each for a 24-week duration, according to a news release from Concert Pharmaceuticals. Read more